Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models

No abstract is available for this paper.

• Publication year

  2007

• Venue

  J. Comput. Aided Mol. Des.

• Publication date

  2007-11-22

• Fields of study

  Medicine, Chemistry, Mathematics, Computer Science

• Identifiers
  DOI 10.1007/s10822-007-9139-6PMID 18034311
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis.

  2007cited by this paper
• Time‐Series QSAR Analysis of Human Plasma Protein Binding Data

  2007cited by this paper
• A Virtual Screening Filter for Identification of Cytochrome P450 2C9 (CYP2C9) Inhibitors

  2007cited by this paper
• Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data

  2007cited by this paper
• Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure.

  2006cited by this paper
• In silico human and rat Vss quantitative structure-activity relationship models.

  2006cited by this paper
• A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries.

  2005cited by this paper
• Greater than the sum of its parts: combining models for useful ADMET prediction.

  2005cited by this paper
• Crystal Structure of Human Cytochrome P450 2D6*

  2005cited by this paper
• A User's Guide to Principal Components: Jackson/User's Guide to Principal Components

  2004cited by this paper
• Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone

  2004cited by this paper
• Performance of (consensus) kNN QSAR for predicting estrogenic activity in a large diverse set of organic compounds

  2004cited by this paper
• Compound lipophilicity for substrate binding to human P450s in drug metabolism.

  2004cited by this paper
• 2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database

  2004cited by this paper
• Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.

  2004cited by this paper
• Quantitative structure-activity relationships (QSARs) for substrates of human cytochromes P450 CYP2 family enzymes.

  2004cited by this paper
• The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution*

  2004cited by this paper
• Crystal structure of human cytochrome P450 2C9 with bound warfarin

  2003cited by this paper
• A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology.

  2003cited by this paper
• Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition

  2003cited by this paper
• Update Information on Human P450s

  2002cited by this paper
• Quantitative structure-activity relationship (QSAR) and three-dimensional QSAR analysis of a series of xanthates as inhibitors and inactivators of cytochrome P450 2B1

  2002cited by this paper
• Structure–activity relationship for human cytochrome P450 substrates and inhibitors

  2002cited by this paper
• Beware of q2!

  2002cited by this paper
• The influence of DMPK as an integrated partner in modern drug discovery.

  2002cited by this paper
• Quantitative Structure-Activity Relationships (QSARs) Within Substrates of Human Cytochromes P450 Involved in Drug Metabolism

  2001cited by this paper
• Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites.

  2001cited by this paper
• Search for Predictive Generic Model of Aqueous Solubility Using Bayesian Neural Nets

  2001cited by this paper
• Development of a Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in Early Drug Discovery

  2001cited by this paper
• In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery.

  2001cited by this paper
• Correlation and prediction of a large blood-brain distribution data set--an LFER study.

  2001cited by this paper
• A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.

  2000cited by this paper
• LeadScope: Software for Exploring Large Sets of Screening Data

  2000cited by this paper
• The use of 'electronic nose' sensor responses to predict the inhibition activity of alcohols on the cytochrome P-450 catalyzed p-hydroxylation of aniline.

  2000cited by this paper
• Quantitative structure‐activity relationship of flavonoids for inhibition of heterocyclic amine mutagenicity

  2000cited by this paper
• Classification and Regression Trees

  2000cited by this paper
• Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli.

  1999cited by this paper
• A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6.

  1999cited by this paper
• The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship.

  1999cited by this paper
• Inhibition and Induction of Cytochrome P450 and the Clinical Implications

  1998cited by this paper
• Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

  1997cited by this paper
• Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors.

  1997cited by this paper
• Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates

  1997cited by this paper
• Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9.

  1996cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• A User's Guide to Principal Components.

  1991cited by this paper
• Multi‐way principal components‐and PLS‐analysis

  1987cited by this paper
• Chemometrics, mathematics and statistics in chemistry

  1984cited by this paper
• Path Models with Latent Variables: The NIPALS Approach

  1975cited by this paper
• p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure

  1964cited by this paper

• In Silico Pharmacological and Pharmacokinetic Study of Marmeline From Bael Fruit for the Treatment of Alzheimer’s Disease

  2025cites this paper
• Quinic acid from Annona muricata Fruit Inhibits Cyclophosphamide Metabolism through Modulation of Cytochrome P450: Implications for Herbal-Drug Interaction

  2025cites this paper
• A Robust Machine Learning Framework Built Upon Molecular Representations Predicts CYP450 Inhibition: Toward Precision in Drug Repurposing

  2023cites this paper
• Design, Synthesis, biological investigations and molecular interactions of triazole linked tacrine glycoconjugates as Acetylcholinesterase inhibitors with reduced hepatotoxicity.

  2021cites this paper
• Exploring the Chemical Space of Cytochrome P450 Inhibitors Using Integrated Physicochemical Parameters, Drug Efficiency Metrics and Decision Tree Models

  2019cites this paper
• Computational prediction of cytochrome P450 inhibition and induction.

  2019cites this paper
• Computational methods and tools to predict cytochrome P450 metabolism for drug discovery

  2019cites this paper
• In silico approaches and tools for the prediction of drug metabolism and fate: A review

  2019cites this paper
• Multiple CH/π Interactions Maintain the Binding of Aflatoxin B1 in the Active Cavity of Human Cytochrome P450 1A2

  2019cites this paper
• The benefits of in silico modeling to identify possible small-molecule drugs and their off-target interactions.

  2018cites this paper
• Prediction of Cytochrome P450-Mediated Metabolism Using a Combination of QSAR Derived Reactivity and Induced Fit Docking.

  2018cites this paper
• Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.

  2017cites this paper
• Towards Predicting the Cytochrome P450 Modulation: From QSAR to Proteochemometric Modeling.

  2017cites this paper
• Advances in Computational Prediction of Regioselective and Isoform‐Specific Drug Metabolism Catalyzed by CYP450s.

  2016cites this paper
• Steps Toward a Virtual Rat: Predictive Absorption, Distribution, Metabolism, and Toxicity Models

  2016cites this paper
• Open Source Bayesian Models. 2. Mining a "Big Dataset" To Create and Validate Models with ChEMBL

  2015cites this paper
• Linear Interaction Energy Based Prediction of Cytochrome P450 1A2 Binding Affinities with Reliability Estimation

  2015cites this paper
• Time-Dependent Inhibition of CYP2C19 by Isoquinoline Alkaloids: In Vitro and In Silico Analysis

  2015cites this paper
• An improved large-scale prediction model of CYP1A2 inhibitors by using combined fragment descriptors

  2015cites this paper
• Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer.

  2015cites this paper
• Rule-Based Prediction Models of Cytochrome P450 Inhibition

  2015cites this paper
• Activity-Limiting Role of Molecular Size: Size-Dependency of Maximum Activity for P450 Inhibition as Revealed by qHTS Data

  2014cites this paper
• Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.

  2014cites this paper
• Multivariate Modeling of Cytochrome P450 Enzymes for 4- Aminoquinoline Antimalarial Analogues using Genetic- Algorithms Multiple Linear Regression

  2014cites this paper
• Quantitative Structure–Activity Relationship (QSAR) Methods for the Prediction of Substrates, Inhibitors, and Inducers of Metabolic Enzymes

  2014cites this paper
• Bilinear Model for the Size‐Dependency of the CYP3A4 Inhibitory Activity of Structurally Diverse Compounds

  2014cites this paper
• Three-dimensional quantitative structure-activity relationship analysis of inhibitors of human and rat cytochrome P4503A enzymes.

  2013cites this paper
• In silico ADMET prediction: recent advances, current challenges and future trends.

  2013cites this paper
• Physicochemical and DMPK in silico models: facilitating their use by medicinal chemists.

  2013cites this paper
• Chapter 10 – Metabolism and pharmacokinetic optimization strategies in drug discovery

  2013cites this paper
• Escape from Flatland 2: complexity and promiscuity

  2013cites this paper
• Elucidation of the biochemical basis for a clinical drug–drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778 875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha

  2013cites this paper
• The challenges involved in modeling toxicity data in silico: a review.

  2012cites this paper
• Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis.

  2012cites this paper
• QSAR and QM/MM approaches applied to drug metabolism prediction.

  2012cites this paper
• Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds.

  2012cites this paper
• The right compound in the right assay at the right time: an integrated discovery DMPK strategy

  2012cites this paper
• QSAR Modelling of CYP3A4 Inhibition as a Screening Tool in the Context of DrugDrug Interaction Studies

  2012cites this paper
• Insights on Cytochrome P450 Enzymes and Inhibitors Obtained Through QSAR Studies

  2012cites this paper
• Strategies for the generation, validation and application of in silico ADMET models in lead generation and optimization

  2012cites this paper
• Drug Metabolism and Pharmacokinetics Quick Guide

  2011cites this paper
• In Silico ADME Tools

  2011cites this paper
• Computational modeling of P450s for toxicity prediction

  2011cites this paper
• IDSite: An accurate approach to predict P450-mediated drug metabolism.

  2011cites this paper
• A comparison of different QSAR approaches to modeling CYP450 1A2 inhibition

  2011cites this paper
• Computational medicinal chemistry in fragment-based drug discovery: what, how and when.

  2011cites this paper
• Quantitative structure–pharmacokinetic relationships

  2011cites this paper
• In-silico ADME models: a general assessment of their utility in drug discovery applications.

  2011cites this paper
• In silico modeling of p450 substrates, inhibitors, activators, and inducers.

  2011cites this paper
• Trainable structure–activity relationship model for virtual screening of CYP3A4 inhibition

  2010cites this paper
• Computer-based substrate specificity prediction for cytochrome P450

  2010cites this paper
• Application of cytochrome P450 drug interaction screening in drug discovery.

  2010cites this paper
• In Silico Approaches to Predict DDIs

  2010cites this paper
• Prediction of Efficacious Inhalation Lung Doses via the Use of In Silico Lung Retention Quantitative Structure-Activity Relationship Models and In Vitro Potency Screens

  2010influential citation
• Forecasting CYP2D6 and CYP3A4 Risk with a Global/Local Fusion Model of CYP450 Inhibition

  2010cites this paper
• Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition.

  2010cites this paper
• Study on herb-drug interactions

  2009cites this paper
• Understanding CYP2D6 interactions.

  2009cites this paper
• Discovery DMPK: changing paradigms in the eighties, nineties and noughties

  2009cites this paper
• Computational approaches to predict drug metabolism

  2009cites this paper
• QSAR of cytochrome inhibitors

  2009cites this paper
• The importance of the domain of applicability in QSAR modeling.

  2008cites this paper
• Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450

  2008cites this paper
• Exploiting QSAR models in lead optimization.

  2008cites this paper
• On the interpretation and interpretability of quantitative structure–activity relationship models

  2008cites this paper